Amphastar Pharmaceuticals Inc., sanofi-aventis, Teva cardiovascular news

SAN said the U.S. Court of Appeals reversed a 2005 ruling by the U.S. District Court for the Central District of California that lifted the 30-month stay on FDA approval of generic versions of SAN's Lovenox enoxaparin. SAN said the case will be returned to the district court. SAN is alleging that Amphastar and TEVA infringe U.S. Patent No. 5,389,618 covering Lovenox. ...